Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Friday, March 26, 2010

New FMO3 paper : A physiological role for flavin-containing monooxygenase (FMO3) in humans?

Flavin mono oxygenase 3 enzyme seems to be very much the ignored xenobiotic enzyme in medical research, despite dealing with probably thousands of substrates in humans, usually oxidizing soft-nucleophilic heteroatom compounds containing sulfur, nitrogen, or phosphorous to non-toxic excretable oxides. There seem to be few researchers interested, and fewer research papers. Someday the pharmaceutical industry will realize it may be a factor in drug metabolism, as can likely be taken for granted by the amount of TMAU people who anticipate bad reactions to drugs. Currently the only 'downside' of having poor FMO3 function is regarded as trimethylaminuira, so it is likely that without our own actions, it will not be until the pharmaceutical industry realizes the 'drug metabolism' factor that frequent serious research will be done into this enzyme.

One of the 'pioneers' in FMO3 research has been Dr Stephen Mitchell of London, who did most of his FMO3 papers in the late 80's and 90's. He also seemed to have a role in organizing the 1st TMAU workshop in 1999.

He has not published an FMO3 paper for most of the last decade, but recently published a new FMO3 paper along with RL Smith, who also has a history in FMO3 research (again, not recently).

The paper is entitled :
A physiological role for flavin-containing monooxygenase (FMO3) in humans?

Unfortunately for us there is not even an abstract available to the public, so we cannot get a summary of what the paper is about. If anyone has access, it would be interesting to know more.


Post a Comment